priority meds semaglutide F.D.A. Approves New Obesity Drug Tirzepatide That Will Compete With Wegovy Medicare, Medicaid to experiment with

Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals

Patients often report losing 2-5 pounds in this four-week period, though individual results depend on baseline weight, diet adherence, and physical activity levels

You may have to spend $12,000 a year for it, especially if theres no insurance coverage

Both classes have demonstrated cardio-renal benefits, favorable safety profiles, and reduced polypharmacy

When to Seek Professional Advice If you have concerns about blood sugar management, weight control, or metabolic health, consulting a healthcare provider is important